Pfizer anticipates a five-year growth phase starting in 2029, driven by patent extensions and R&D investments.
Pfizer (PFE) expects revenue growth to rebound to high-single-digit rates beginning in 2029, according to CEO Albert Bourla. The outlook follows a period of declining sales and stagnant stock performance, despite a 6.6% dividend yield compared to the S&P 500’s 1.1% average.
The company’s growth projection hinges on patent settlements for Vyndamax, delaying revenue declines until 2031. Pfizer also plans 20 pivotal studies this year and four regulatory decisions in 2026, aiming to strengthen its pipeline. Prior investments in R&D are expected to support long-term expansion.
Pfizer’s stock has struggled amid growth concerns, though management’s optimism may shift investor sentiment if execution aligns with targets.